Sign Out
Cardiac glycosides: The effect of the glycosides can be enhanced by potassium deficiency.
Saluretics/laxatives: Potassium excretion is enhanced.
Antidiabetic agents: The blood sugar lowering effect is reduced.
Coumarin derivatives: The efficacy of coumarin anticoagulants may be reduced or enhanced.
Non-steroidal antiphlogistic/antirheumatic agents, salicylates and indomethacin: The risk of gastrointestinal haemorrhages is increased.
Non-depolarising muscle relaxants: Muscle relaxation may be prolonged.
Atropine and other anticholinergics: The concurrent use of PRED may result in additional increases in intraocular pressure.
Praziquantel: Glucocorticoids may lower the praziquantel concentrations in the blood.
Chloroquine, hydroxychloroquine, mefloquine: There is an increased risk of occurrence of myopathies, cardiomyopathies.
Somatropin: The efficacy of somatropin may be reduced.
Estrogens (e.g. oral contraceptives): May enhance the efficacy of glucocorticoids.
Liquorice: Inhibition of the metabolism of glucocorticoids is possible.
Rifampicin, phenytoin, barbiturates, bupropion and primidone: The efficacy of glucocorticoids is reduced.
Cyclosporine: The blood levels of cyclosporine are increased. There is an increased risk of seizures.
Amphotericin B: The risk of hypokalaemia may be increased.
Cyclophosphamide: The effects of cyclophosphamide may be enhanced.
ACE inhibitors: Increased risk of occurrence of blood count changes.
CYP3A inhibitors: Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.
Aluminium and magnesium antacids: The absorption of glucocorticoids is reduced.
Continue with Google